Grants for Public housing authorities - Health

This Notice of Funding Opportunity (NOFO) invites applications for sites to participate in the Genomic Medicine eConsult Research Network, hereafter referred to as the eConsult Network. The eConsult Network will consist of 2-3 sites working with NHGRI to conduct research on the impact of and methods for implementing regional clinician-to-clinician genomic medicine eConsult services. Specifically, sites will be funded to research how to best design, develop, and implement regional genomic medicine eConsult services; provide outreach to potential users, including those at underserved settings; and assess the impact on key stakeholders while developing successful implementation strategies and resources that can be broadly shared and adopted.

This funding opportunity supports innovative research aimed at understanding and addressing mood and psychotic disorders that may arise or worsen during the menopause transition, encouraging collaboration among interdisciplinary researchers.

This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research for people who use drugs. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons living with HIV.

This funding opportunity supports the development and use of research infrastructure that fosters interdisciplinary collaborations to address complex aging-related scientific questions, particularly benefiting diverse and underserved populations.

This grant provides funding to organizations that aim to improve healthcare delivery and reduce disparities for underserved populations by implementing evidence-based practices and fostering collaboration among healthcare providers, government agencies, and community organizations.

Notice of Funding Opportunity summary:The United States Agency for International Development (USAID) is seeking applications for aCooperative Agreement from qualified entities to implement the Urban Health Activity. Eligibilityfor this award is not restricted.USAID intends to make an award to the applicant who best meets the objectives of this fundingopportunity based on the merit review criteria described in SECTION E of this Notice of FundingOpportunity (NOFO), subject to a risk assessment. The applicant receiving an award will be theRecipient. Eligible parties interested in submitting an application are encouraged to read thisNOFO thoroughly to understand the type of program sought, application submissionrequirements, and selection process.Activity short summary:USAID/Uganda plans to award a five-year Cooperative Agreement to enhance health systemresilience and improve the survival and well-being of the residents of Kampala city, Mukono, andWakiso districts (hereafter referred to as the Target Districts) (the Activity). The Activity willstrengthen public and private health systems at the facility and community levels to deliverresponsive, timely, evidence-based, quality services. The Activity will strengthen maternal,newborn, and child health (MNCH); malaria; family planning (FP) / reproductive health (RH);nutrition; and Global Health Security (GHS) services in the Target Districts.

This funding opportunity provides financial support for U.S.-based institutions to organize scientific conferences that promote collaboration and diverse participation in health and science research.

This funding opportunity provides long-term financial support to innovative researchers in environmental health sciences, allowing them to pursue ambitious projects and consolidate existing grants while focusing on mentoring and diversity.

This funding opportunity supports postdoctoral researchers from underrepresented backgrounds in neuroscience, helping them transition to independent faculty positions while providing financial support for their research.

This funding opportunity provides financial support to a variety of organizations working in Kenya to strengthen laboratory systems for diagnosing and treating HIV, TB, and related health threats, ultimately aiming to improve healthcare access and quality.

This funding opportunity supports U.S. institutions in creating centers focused on advancing research in nutrition and obesity through collaborative efforts and innovative projects.

This funding opportunity supports researchers investigating new biological, environmental, and social factors contributing to liver cancer in the U.S., particularly in relation to established risk factors and health disparities.

This funding opportunity supports community-based arts programs designed to enhance the health and well-being of military personnel, veterans, and their families through creative engagement.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites U01 cooperative agreement applications for Physical Sciences-Oncology Network (PS-ON). The goal of the PS-ON is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The research projects funded through this FOA, individually and as a collaborative Network along with other funded research projects, will support transdisciplinary research that: (1) drives a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to support the archiving and documentation of existing data sets within the scientific mission of the NICHD in order to enable secondary analysis of these data by the scientific community. The highest priority is to archive original data collected with NICHD funding. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The NOFO is expected to be published in July 2024 with an expected application due date in October 2024. This NOFO will utilize the R03 activity code. Details of the planned NOFO are provided below.

The purpose of this Notice of Funding Opportunity (NOFO) is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms based on penetration and efflux of small molecules to facilitate therapeutic discovery for select Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Pseudomonas aeruginosa. A number of Gram-negative bacterial pathogens are associated with the alarming increase in rates of drug resistance in healthcare and community settings. This group includes carbapenem-resistant Acinetobacter , carbapenem-resistant Enterobacterales (CRE), and MDR Pseudomonas aeruginosa that have been designated as “urgent” or “serious” threats in a recent report by the Centers for Disease Control and Prevention (CDC). A significant threat arises from the lack of effective therapeutic options available to treat some of these infections and is exacerbated by the scarcity of novel compounds effective against antimicrobial resistant (AR) and multidrug-resistant (MDR) Gram-negative bacteria in the discovery and development pipeline. In recent years, several public forums (including NIAID-sponsored workshops) identified the lack of understanding of the principles that govern compound penetration into, and efflux out of, Gram-negative bacteria as a key bottleneck for the rational discovery of novel lead therapeutic compounds. The paucity of suitable assays/tools/models to inform structure-activity relationships and guide optimization of whole cell penetration (and efflux avoidance) is reflected in the failure of medicinal chemistry efforts to advance novel chemical classes of compounds with Gram-negative activity. As more Gram-negative bacteria become resistant to antimicrobials and therapeutic options become limited or nonexistent, it becomes imperative to understand and rationalize the principles that allow molecules to penetrate Gram-negative bacteria, while avoiding efflux and overt toxicity toward eukaryotic cells. Therefore, developing new assays, tools, and models is paramount for overcoming this key bottleneck and facilitating the development of novel compounds targeting Gram-negative pathogens. Research Objectives and Scope The objective of this NOFO is to support milestone-driven projects focused on developing and utilizing novel predictive models, assays, tools, and/or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens. This NOFO also supports the preclinical development of novel Gram-negative antibacterial therapeutics based on the tools and models hereby developed. Applications must focus on one or more of the following Gram-negative bacterial pathogens: carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales (CRE), and/or MDR Pseudomonas aeruginosa. Projects should complete assay/tool/model development prior to the end of the third year of the project period and initiate discovery activities to demonstrate its utility in supporting a corresponding medicinal chemistry program to generate a lead chemical series with demonstrated activity against one or more targeted Gram-negative bacteria. This NOFO will also support subsequent preclinical development of a promising lead antibacterial. Given the complex challenges of this research, this initiative encourages applications from multi-disciplinary teams composed of relevant experts in areas such as bacterial physiology, microbiology, bacterial membrane biology, medicinal chemistry, pharmacology, computation, and specialized technologies (microscopy, spectroscopy, electrophysiology, machine learning, etc.), as appropriate. Collaboration with, and utilization of, the NIAID Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB), is recommended for completion of project relevant medicinal chemistry tasks. Close collaboration between academic and industry partners is highly encouraged to optimally combine innovative basic science with drug discovery expertise and proper access to compound libraries more typically available from industry. Examples of assay and model development activities include, but are not limited to: Quantitative cellular (or model system) assays to measure drug penetration and efflux, independent from standard minimum inhibitory concentration (MIC) testing; Innovative quantitative assays to measure drug concentrations in the bacterial cytoplasm and/or periplasmic space; Innovative technologies for dissecting and assessment of the kinetics of drug penetration and efflux from bacteria; and Computational algorithms for describing/predicting physical-chemical properties/guidelines needed by small molecules for optimal Gram-negative penetration and efflux avoidance. Applicants should demonstrate the utility of the developed tools and/or assays to predict and measure potency of candidate therapeutics against Gram-negative targets through one or more approaches. For example, using the developed models and/or assays to guide a medicinal chemistry campaign aimed at producing a novel chemical series with Gram-negative activity; screening existing libraries using the computational algorithms developed as a tool to find compounds with Gram-negative activity; or profiling existing libraries of compounds with known Gram-negative activity. Applications including the following will be considered non-responsive and will not be reviewed: Projects that do not focus on at least one select Gram-negative pathogen (carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, or MDR Pseudomonas aeruginosa); Projects focused only on Gram-positive bacteria or Mycobacterium tuberculosis; Projects that do not focus on penetration and efflux of small molecules; Applications not containing a Milestone and Timeline attachment; Applications proposing Clinical trials; and Research on HIV/AIDS.

This funding opportunity supports researchers in developing innovative animal models and biological tools to advance the understanding of Down syndrome and its related health conditions.

This funding opportunity supports innovative research projects that explore how climate change affects cancer risks, treatment, and survivorship, with a focus on developing solutions to mitigate these impacts and address health inequities.

The "Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research" grant aims to fund exploratory research projects that further develop and validate innovative technologies for analyzing molecular and cellular aspects of cancer, with the goal of improving cancer research, detection, diagnosis, treatment, and understanding of health disparities.

This grant provides funding for researchers to investigate the biological mechanisms behind adverse effects related to anti-beta-amyloid immunotherapy in Alzheimer's disease, with the goal of developing strategies to protect the blood-brain barrier and improve treatment safety.